IQVIA’s most recent Global Use of Medicines report projected that market introductions of new biosimilar and generic drugs will increase projected losses for originator products from $111 billion to $192 billion over the next five years.
Formulary Watch
Latest News
All News
Advertisement
HyQvia is now available a maintenance therapy for adults with chronic inflammatory demyelinating polyneuropathy, which can lead to weakness and loss of feeling in the arms and legs.
With a cost of $2.2 million, Casgevy is a CRISPR/Cas9 gene-edited cell therapy that is now also approved to treat beta thalassemia. It was approved to treat sickle cell disease in December 2023.
Adstiladrin delivers a gene that encodes for the interferon alpha-2b protein, and it provides an option for those at high risk of recurrence and metastatic bladder cancer.
Less flexible plans, such as health maintenance organizations, are more likely to use biosimilar therapies than more flexible plans.
UnitedHealth Group executives attribute the increase of revenue at Optum Rx to the addition of new clients, expanded relationships with existing clients, and advancements in services.
Regulators will continue to evaluate a possible link by reviewing meta-analysis of clinical trials across all GLP-1 products and analyzing postmarketing data in the Sentinel System.
Vevye is a water- and preservative-free solution of cyclosporine, which allows for improved bioavailability.
Clients are cautious about how the cost in “cost-plus” programs is determined, how rebates factor in and the benchmarks used, says Navitus’s Brent Eberle.
The transaction is valued at about $575 million. The sale is part of Rite Aid’s restructuring plan after filing for bankruptcy in October 2023.
Advertisement
Tivdak was granted accelerated approval in September 2021 to treat patients with recurrent or metastatic cervical cancer. The goal date for full approval is May 9, 2024.
The FDA cited issues with a third-party manufacturing company. Zolbetuximab is being reviewed to treat patients with stomach cancer.
Zelsuvmi, a first-in-class topical treatment approved for patients with molluscum contagiosum, will be available in the second half of 2024.
Adam Fein, founder of Drug Channels, said the acquisition will allow the company to upgrade its technology, grow the company and provide live and in-person events.
If approved, Accord’s biosimilar would treat several autoimmune conditions and would be launched no later than May 15, 2025
CVS Caremark has entered into an agreement with AbbVie, the manufacturer of Humira, to supply Cordavis with Humira to develop a cobranded product. Cordavis is a CVS company developing private label therapies.
Zilbrysq has a list price $1,047.19 for a 23 mg syringe. It is UCB’s second treatment for patients with myasthenia gravis.
Loqtorzi has a wholesale acquisition cost of $8,892.03 per single-use vial.
The presence of glass can lead to serious adverse events, including inflammation of a vein and blockage of blood vessels or life-threatening blood clots.
Wainua is approved to treat patients with hereditary transthyretin-mediated amyloid polyneuropathy and can be self-administered via an auto-injector.
The FDA has seized thousands of units of counterfeit Ozempic 1 mg.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Retatrutide shows substantial weight loss, glycemic control in obesity and type 2 diabetes | ADA 2026
2
Pivotal trial is recruiting for monthly GLP-1 for weight loss | ADA 2026
3
CONNECT data support CGM use in non-insulin type 2 diabetes management | ADA 2026
4
‘Fierce compassion’ could be key to minimizing shame in HIV patients
5